Steven Fruchtman, MD

Dr. Fruchtman joined Onconova in January 2015 as Chief Medical Officer and was promoted to President & CEO in July 2018. He has extensive experience in large and small biopharmaceutical companies and has led successful clinical development programs while serving in senior positions at Ortho Biotech Products, Novartis, Allos Therapeutics, Spectrum Pharmaceuticals, and Syndax Pharmaceuticals leading to Health Authority approvals for several new chemical entities in various malignancies. Previously, Dr. Fruchtman was on the faculty of the Mount Sinai School of Medicine and the Director of the Stem Cell Transplantation and Myeloproliferative Disorder Programs at Mount Sinai Hospital in New York City. He is an author of more than 170 lectures, presentations, books, chapters, and abstracts and served as an external reviewer for multiple medical journals. Dr. Fruchtman received his medical degree from New York Medical College.